IRLAB Therapeutics AB (publ) Asset Resilience Ratio

Latest as of December 2025: 59.23%

IRLAB Therapeutics AB (publ) asset resilience ratio. IRLAB Therapeutics AB (publ) (IRLAB-A) has an Asset Resilience Ratio of 59.23% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IRLAB Therapeutics AB (publ) (IRLAB-A) defensive interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Skr81.86 Million

≈ $8.81 Million USD Cash + Short-term Investments

Total Assets

Skr138.21 Million

≈ $14.87 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio of IRLAB Therapeutics AB (publ) (2016–2025)

Asset resilience ratio of IRLAB Therapeutics AB (publ) from 2016 to 2025. This chart shows how IRLAB Therapeutics AB (publ)'s Asset Resilience Ratio has changed over time. Read how much debt does IRLAB Therapeutics AB (publ) carry for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down IRLAB Therapeutics AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see IRLAB Therapeutics AB (publ) (IRLAB-A) total assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr81.86 Million	59.23%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr81.86 Million	59.23%

Asset Resilience Insights

Very High Liquidity: IRLAB Therapeutics AB (publ) maintains exceptional liquid asset reserves at 59.23% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

IRLAB Therapeutics AB (publ) Industry Peers by Asset Resilience Ratio

Compare IRLAB Therapeutics AB (publ)'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Bavarian Nordic CO:BAVA	Biotechnology	10.83%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

IRLAB Therapeutics AB (publ) Asset Resilience Ratio by Year (2016–2025)

IRLAB Therapeutics AB (publ) asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for IRLAB Therapeutics AB (publ).

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	59.23%	Skr81.86 Million ≈ $8.81 Million	Skr138.21 Million ≈ $14.87 Million	+10.10pp
2024-12-31	49.13%	Skr66.92 Million ≈ $7.20 Million	Skr136.21 Million ≈ $14.66 Million	-13.72pp
2023-12-31	62.84%	Skr111.31 Million ≈ $11.98 Million	Skr177.12 Million ≈ $19.06 Million	-15.28pp
2022-12-31	78.12%	Skr252.78 Million ≈ $27.20 Million	Skr323.56 Million ≈ $34.82 Million	-6.94pp
2021-12-31	85.07%	Skr401.90 Million ≈ $43.25 Million	Skr472.45 Million ≈ $50.84 Million	+10.21pp
2020-12-31	74.85%	Skr277.01 Million ≈ $29.81 Million	Skr370.07 Million ≈ $39.83 Million	+21.73pp
2019-12-31	53.12%	Skr110.53 Million ≈ $11.89 Million	Skr208.07 Million ≈ $22.39 Million	-6.65pp
2018-12-31	59.77%	Skr134.44 Million ≈ $14.47 Million	Skr224.94 Million ≈ $24.21 Million	+13.93pp
2017-12-31	45.84%	Skr74.71 Million ≈ $8.04 Million	Skr162.97 Million ≈ $17.54 Million	+23.09pp
2016-12-31	22.75%	Skr25.74 Million ≈ $2.77 Million	Skr113.11 Million ≈ $12.17 Million	--

pp = percentage points

About IRLAB Therapeutics AB (publ)

ST:IRLAB-A Sweden Biotechnology

Market Cap

$18.49 Million

Skr171.84 Million SEK

Market Cap Rank

#25208 Global

#501 in Sweden

Share Price

Skr2.03

Change (1 day)

+0.00%

52-Week Range

Skr1.20 - Skr2.40

All Time High

Skr104.95